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Introduction
Over the last few years, much has been done to develop
guidelines on the basis of the strongest possible evidence
because this allows an accurate description of the qual-
ity and/or degree of uncertainty of the recommendations
and provides physicians with a valuable tool for judicious
decisions. However, creating and updating evidence-based
guidelines is extremely costly, and so the nephrological
community has been trying to build up a single set of in-
ternational guidelines under the aegis of Kidney Disease
Improving Global Outcomes (KDIGO) [1]. As part of this
unifying effort, the working group responsible for the 2006
update of the National Kidney Foundation–Kidney Disease
Outcome Quality Initiative (NKF-KDOQI) guidelines on
anaemia management in patients with chronic kidney dis-
ease (CKD) [2], and the 2007 update on haemoglobin (Hb)
targets [3], included members from Europe, Middle East,
Mexico and Canada. However, this international effort may
not be correctly perceived by European nephrologists, who
sometimes feel that differences in practice patterns make it
difficult to apply guidelines developed outside Europe; on
the other hand, the latest update of the European Best Prac-
tice Guidelines (EBPG) [4] may appear outdated in some
respects.
A specially appointed ERA-EDTA Work Group met
in Paris to discuss European guideline planning in early
January 2008, and agreed that the Association should con-
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tinue producing and updating guidelines in collaboration
with KDIGO [5]. It also agreed that ERA-EDTA should
issue suggestions for clinical practice in areas in which ev-
idence is lacking or weak, which will be presented as ‘po-
sition statements’ rather than clinical guidelines [5]. It was
also decided to issue position statements about guidelines
(recommendations issued by other bodies, of which the cur-
rent publication is the first result). Finally, the group opted
to change the name EBPG to European Renal Best Prac-
tice (ERBP) as a means of acknowledging that, especially
in nephrology, it is difficult to generate real ‘guidelines’
because of the lack of sufficient evidence.
In this context, and while awaiting the publication
of the KDIGO anaemia guidelines possibly in 2011, an
ad hoc work group was commissioned by the ERBP Ad-
visory Board to give its opinion on the ‘hot topic’ of Hb
targets, including recently raised issues that were not cov-
ered by KDOQI in 2006 [2]. These points are summarized
in the present position paper, which is not intended to rep-
resent a set of new guidelines as it is not the result of a
systematic review of the evidence.
NKF-KDOQI update, 2006
In May 2006, the NKF published a revised set of guide-
lines on managing anaemia in CKD [2]. The Guideline
Committee attempted to integrate new evidence using the
2004 EBPG revision [4] and the 2000 KDOQI guidelines
as a starting point [6]. The update also involved a system-
atic review of the evidence based on an extensive search
of the literature and the grading of the strength of the
evidence, and separated evidence-based guidelines, which
could be used to measure clinical performance when ap-
propriate, and clinical practice recommendations primarily
based on expert judgement. The result was a solid document
summarizing the evidence available up until September
2005.
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Haemoglobin target: NKF-KDOQI update,
September 2007
In 1997, the DOQI guidelines on anaemia treatment recom-
mended a target range for haematocrit/Hb of between 33%
(Hb 11 g/dl) and 36% (Hb 12 g/dl) [7]. While waiting for
the results of clinical trials concerning complete anaemia
correction other than Besarab’s study [8], almost similar
recommendations were made in the 2000 update of the
KDOQI guidelines [6] and by EBPG [4] although no upper
limit was defined for the early stages of CKD, while nor-
malization of Hb levels was generally not recommended for
patients with diabetes or cardiovascular disease. The 2006
update of the NKF-DOQI guidelines recommended that
the target Hb range should generally be ≥11.0 g/dl (lower
limit) and stated that there was insufficient evidence to
recommend routinely maintaining Hb levels of ≥13.0 g/dl
in ESA-treated patients (upper limit) [2]. At this time, the
available findings of randomized clinical trials and meta-
analysis [9] did not suggest any major effect of complete
anaemia correction on hard, intermediate or surrogate end-
points except the quality of life. Two large-scale random-
ized trials studying the effect of complete anaemia correc-
tion on mortality in patients not on dialysis were published
in November 2006 [10,11]. In the CREATE study [10],
603 patients with stage 3 and 4 CKD and mild–moderate
anaemia were randomly assigned to a target Hb range of
13–15 g/dl (normal range) or 10.5–11.5 g/dl (subnormal
range). During the 3 years of the study, the number of car-
diovascular events was not significantly different between
the two groups (58 versus 47) and there was no difference
in the frequency of death from any cause or cardiovascu-
lar causes, nor in the incidence of hospitalization. How-
ever, patients randomized to complete anaemia correction
had a shorter time in need of dialysis. The CHOIR study
[11] was an open-label trial in which 1432 CKD patients
were randomly assigned to achieve an Hb level of 14.3 g/dl
or 11.3 g/dl. The median duration of the follow-up was
16 months, but the trial was stopped early for safety and
futility because it had become unlikely that the group ran-
domized to the higher Hb target would obtain any ben-
efit and was associated with an increased risk of reach-
ing the primary composite end-point (death, myocardial
infarction or hospitalization because of congestive heart
failure or stroke). Despite the differences in their popu-
lations and the results of secondary analyses, these two
large-scale, prospective randomized trials showed that at-
tempts to correct anaemia completely do not reduce mortal-
ity or cardiovascular disease in CKD patients in comparison
with partial anaemia correction [10,11]. A meta-analysis by
Phrommintikul et al. [12] (which also included these two
trials) led to the conclusion that the patients in the higher Hb
target group were at significantly greater risk of all-cause
mortality and arterio-venous access thrombosis.
In March 2007, the US Food and Drug Administration
(FDA) changed the labelling for erythropoiesis stimulating
agents (ESAs) and added a boxed warning stating that Hb
targets of >12 g/dl should be avoided because of the in-
creased risk of death and serious cardiac events, and also
noted that ESAs should increase Hb only to the lowest level
necessary to avoid transfusion.
These recommendations created considerable confusion
and concern, and the new evidence was considered sig-
nificant enough to justify updating the statements by the
NKF-KDOQI guideline working group concerning Hb tar-
gets. An Evidence Review Team analysed all data from
randomized controlled trials of anaemia management in
CKD, including CREATE [10], CHOIR [11] and four addi-
tional studies not included in the previous update. Combin-
ing mortality outcomes from eight studies involving 3038
subjects with non-dialyzed CKD revealed no difference be-
tween the higher and lower Hb target [3], but combining
adverse cardiovascular events from six studies involving
2850 subjects showed an increased risk among the patients
assigned to the higher Hb targets (a RR of 1.24, 95% CI
1.02–1.51) [3], although it is worth noting that the CHOIR
and CREATE studies contributed most of the weight to
the analysis. Among dialysis patients, combining mortality
(four studies, 2391 subjects) or cardiovascular outcomes
(three studies, 1975 subjects) showed no statistically sig-
nificant difference between the higher and lower Hb level;
here the study by Besarab et al. [8] contributed most of the
weight to the analysis.
The meta-analysis by NKF-KDOQI differed from that
by Phrommintikul et al. [12] as it included studies with
a longer minimum follow-up (without any restriction on
study size), kept the data concerning dialyzed and non-
dialyzed patients separate and had a broader definition of
cardiovascular outcomes as it combined all cardiovascular
events (Phrommintikul et al. only considered myocardial
infarction).
On the basis of these results, the NKF-KDOQI working
group reformulated its recommendations by stating that
the Hb target in patients receiving ESAs should generally
be 11–12 g/dl and not >13 g/dl because ‘the possibility of
causing harm weighs more heavily than the potential of imp-
roving the quality of life and decreasing transfusions’ [3].
Kidney Disease Improving Global Outcomes
(KDIGO)
KDIGO, which was established in 2003, is a non-profit
foundation governed by an international board that has the
aim of ‘improving the care and outcomes of kidney disease
patients worldwide by promoting coordination, collabora-
tion and integration of initiatives to develop and implement
clinical practices guidelines’. In October 2007, it called a
meeting to coordinate a response to the issue of anaemia
management after the publication of the NKF-KDOQI up-
date concerning Hb targets [13]. On the basis of the avail-
able evidence, it was concluded that an Hb level of >13 g/
dl may be associated with harm in subjects treated with
ESA; that levels of 9.5–11.5 g/dl are associated with better
outcomes than those of >13 g/dl, but that there was no ev-
idence either way for intermediate levels (11.5–13 g/dl) in
comparison with higher or lower levels.
Limitations of the current knowledge of CKD-related
anaemia were also identified, as well as topics for future
research.
It was generally agreed that there were insufficient
new data to justify an immediate revision of the anaemia
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guidelines. On the basis of the anticipated results of key
on-going studies, particularly the Trial to Reduce cardio-
vascular Events with Aranesp(R) (darbepoetin alfa) Ther-
apy (TREAT) [14], which is a 4000-patient, multicentre,
double-blind RCT, designed to determine the impact of
anaemia therapy with darbepoetin alpha on mortality and
non-fatal cardiovascular events in patients with CKD and
type 2 diabetes mellitus, it was planned to start a review of
the new evidence no earlier than 2009 with the expectation
of completing it in 2011. Given the clear need to avoid du-
plication, these guidelines will be the result of a coordinated
effort undertaken by KDIGO.
The position of ERBP
Haemoglobin target
In 2004, EBPG suggested an Hb target of ≥11 g/dl; values
of >14 g/dl were considered undesirable in general, and
the limit for patients with cardiovascular disease was set at
12 g/dl. Caution of not exceeding the value of Hb concen-
trations ≥12 g/dl was recommended to be given also for
patients with diabetes, especially if they had concurrent pe-
ripheral vascular disease. Since September 2007, when the
KDOQI Hb target update was published, no further data
from new clinical trials have been published. In response to
a request from the editors of the New England Journal of
Medicine, the authors of the Normal Hematocrit Study [8]
provided supplementary data about events occurring after
the dataset had been analysed by the Independent Data and
Safety Monitoring Committee [15]; the inclusion of these
additional events in the survival analysis did not substan-
tially modify the risks of death or myocardial infarction.
• In the opinion of the ERBP Work Group, it appears rea-
sonable to maintain the lower limit of the target, although
the actual evidence for choosing this value is also very
limited. On the basis of new evidence, Hb values of 11–
12 g/dl should be generally sought in the CKD population
without intentionally exceeding 13 g/dl.
Although harm is possible when aiming at higher Hb tar-
gets, it is likely that this applies most to selected populations
such as patients with diabetes and/or clinically significant
cardiovascular disease. However, current evidence shows
no benefit for higher targets in any subgroup and increased
expenditure on higher ESA doses.
A secondary analysis of the CHOIR trial showed that
patients in the high target group who reached an Hb level
of 11 g/dl but could not reach 13 g/dl showed a higher rate of
adverse outcomes, and the patients who needed a high ESA
dose had a 6% greater risk of reaching a study end-point
regardless of the target [16].
• The ERBP Work Group believes that there is a need for
better understanding as to whether any harm may be asso-
ciated with attempts to reach higher Hb values in patients
with comorbidities or those who are hyporesponsive to
ESAs.
It is more difficult to keep patients within a narrow target
window mainly because of haemoglobin variability [17],
and so physicians need to accept that patients may be be-
low or above the target for a given period of time. The
possibility that there may be a causal relationship between
Hb variability and patient outcome has been suggested by
association studies [18,19].
• The ERBP Work Group agrees with the recent position
of KDIGO [13] that the available quality of life data vary
in quality and are often inconclusive. As more reliable
methods of assessing patient-related outcomes and func-
tional status are now available, there is room for new
studies testing the effect of anaemia correction on more
robust measures of the quality of life.
Anaemia evaluation
In 2004, EBPG defined anaemia in CKD patients on the ba-
sis of their gender and age. In patients living below 1500 m,
Hb values were considered below normal if they were
<11.5 g/dl in women and <13.5 g/dl in men (<12 g/dl
in those aged >70 years), and it was recommended that
an anaemia work-up be started when Hb levels fall below
these limits.
In 2006, KDOQI modified this definition by giving a
single criterion for diagnosing anaemia in adult males (Hb
<13.5 g/dl, regardless of age) because the decrease in Hb
among males aged >60 years is often attributable to con-
current diseases.
• The ERBP Work Group agrees with this new definition.
Targets for iron therapy
Traditionally, the most widely used iron tests are serum
ferritin and transferrin saturation (TSAT) levels. In 2004,
EBPG recommended lower limits of ferritin and TSAT of,
respectively, 100 ng/ml and 20%, with target ranges of re-
spectively 200–500 ng/ml and 30–50%. In 2006, and in light
of patient safety, KDOQI defined the lower ferritin limit on
the basis of CKD status (100 ng/ml in non-HD-CKD and
200 ng/ml in HD-CKD); if serum ferritin levels are >500
ng/ml, iron administration should be discouraged.
No key study has been published since the publication of
the 2006 KDOQI guidelines, but it is interesting to note the
results of the Dialysis Patients’ Response to IV Iron with
Elevated Ferritin (DRIVE) trial [20], which evaluated the
efficacy of intravenous ferric gluconate in 134 patients with
high ferritin (500–1200 ng/ml) and low transferrin satura-
tion levels (TSAT ≤ 25%) who were anaemic despite a high
rHuEPO dose (≥225 IU/kg/week or ≥22 500 IU/week). Af-
ter 6 weeks, the patients receiving ferric gluconate (125 mg
i.v. at eight consecutive haemodialysis sessions) showed
a significant increase in Hb in comparison with controls.
However, the study has a number of limitations because,
given the short follow-up, it provides no information about
safety and iron overload.
• The ERBP Work Group agrees with the recommenda-
tions of the KDOQI guidelines.
New ESAs
The 2004 revision of EBPG and the 2006 KDOQI guide-
lines [2] made recommendations concerning the use of the
three ESAs available at that time: epoetin alpha, epoetin
beta and darbepoetin alpha. Since then, two other ESAs
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have been introduced: epoetin delta and continuous ery-
thropoiesis receptor activator (CERA).
Epoetin delta. Epoetin delta has the same amino acid
sequence as endogenous epoetin, and epoetin alpha and
beta, but is synthesized in human cells [21], a pro-
cess that may theoretically circumvent problems arising
from species-dependent differences in protein folding or
post-translational modifications. However, such theoretical
problems have so far not become obvious and the phar-
macodynamics and pharmacokinetics of epoetin delta are
also similar to those of other recombinant human erythro-
poietins [22]; clinical trials indicate that it corrects renal
anaemia in rHuEPO-naive patients [23] and can be used in
the maintenance therapy of those already receiving epoetin
alpha [24–27].
• In the opinion of the group, epoetin delta should be ad-
ministered similarly to epoetin alpha.
Continuous erythropoiesis receptor activator (CERA).
CERA is a modified recombinant human erythropoietin
(rHuEPO) that incorporates a large polyethylene glycol
polymer [28], which increases its molecular weight (∼60
kD) and alters pharmacodynamics and pharmacokinetics.
In particular, CERA has a considerably longer half-life than
the other licensed ESAs (∼130 h) [29,30]. It also has a
lower total binding affinity for the erythropoietin receptor
than epoetin beta, mainly due to a much slower association
rate [31]. These receptor-binding properties may contribute
to its distinct pharmacological characteristics. Phase II and
III studies have shown that it corrects anaemia in EPO-
naive patients, and has a recommended starting dose of
0.60 µg/kg once every 2 weeks [32–35]. Other phase II and
III clinical trials have tested its non-inferiority for mainte-
nance therapy with a currently available ESA [36–41], and
found that it can be given once every 4 weeks i.v. or s.c.
during the maintenance phase.
• Based on the evidence available, the frequency of CERA
administration should be once every 2 weeks for correc-
tion and once every 4 weeks for maintenance.
• The ERBP Work Group considers the safety and tolera-
bility of CERA to be similar to that of other ESAs.
Biosimilars
In December 2004, the patent of epoetin alpha expired in
Europe, and that of epoetin beta expired in many European
countries in 2005, thus opening the way to biosimilars.
HX575, a biosimilar of epoetin alpha, received marketing
authorization throughout the European Union in August
2007; it is marketed by three companies under three differ-
ent brand names. In December 2007, epoetin zeta, which is
another biosimilar of epoetin alpha, received EMEA mar-
keting authorization as well.
While biosimilars may remove some of the current eco-
nomical pressures on health care systems, the safety record
of these compounds is much smaller as compared to the
original ESAs and they need to be submitted to the same
stringent pharmacovigilance measures as the other ESAs.
To ensure this it appears mandatory that biosimilars are not
used in exchange of other rHUEPOs without physician’s
approval. It is also noteworthy that ESA biosimilars are
currently only approved for intravenous administration in
CKD patients.
• The ERBP Work Group recommends stringent pharma-
covigilance for biosimilars of epoetin alpha that can be
administered only intravenously.
Pure red cell aplasia
Antibody-mediated pure red cell aplasia (PRCA) is a rare
but serious adverse event related to ESA therapy. There has
been an upsurge in the number of PRCA cases since 1998,
mainly associated with the subcutaneous use of Eprex R©,
the epoetin alpha produced outside the United States [42].
This coincided with a change in the Eprex R© formulation
(the replacement of human serum albumin by polysorbate
80 was requested by EMEA because of the fear of bovine
spongiform encephalopathy), and it has been postulated
that polysorbate 80 may elicit the formation of possibly im-
munogenic epoetin-containing micelles [43]. Alternatively,
it has been suggested that leachates released by the uncoated
rubber stoppers of the pre-filled syringes may interact with
polysorbate 80 and act as an adjuvant of the immune reac-
tion. The breaking of cold chain is potentially an important
factor.
The subcutaneous use of Eprex R© in CKD patients had
been contraindicated in Europe by regulatory authorities
since December 2002, and was strongly discouraged in
Canada and Australia.
The number of reported cases of PRCA has decreased
sharply since 2003 and with no more cases reported in
2007. This may be due to a change in the route of admin-
istration, the reinforcement of the product cold chain or
the elimination of uncoated rubber syringe stoppers. The
regulatory authorities consider the latter as the most signif-
icant factor and have recently readmitted the subcutaneous
use of Eprex R© when the vascular access is not available in
conjunction with an extensive pharmacovigilance plan.
• The ERBP Work Group considers it essential that sus-
pected PRCA cases are carefully worked up and con-
firmed cases are carefully monitored.
As there were few data concerning the outcome of ESA
treatment in patients who have recovered from PRCA, the
2004 EBPG could not make any recommendation about
whether to resume its administration in such patients. In
2005, a follow-up report concerning 170 CKD patients
who developed epoetin-associated PRCA was made avail-
able by the Research on Adverse Drug Events and Reports
(RADAR) Project [44]. Of the 34 patients who received
epoetin after the onset of PRCA, 56% recovered epoetin
responsiveness; the highest rate of epoetin responsiveness
was observed among those who had no detectable anti-
erythropoietin antibodies at the time of epoetin administra-
tion (89%).
• Given these data, the ERBP Work Group considers that
retreatment with ESA can be considered in patients with
a history of PRCA, if anti-EPO antibodies are no longer
detectable.
It has very recently been reported that hematide, a non-
peptidic erythropoietin receptor agonist that is currently
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under clinical development, corrects the anaemia induced
by the presence of anti-erythropoietin antibodies [45] as
previously shown in a rat PRCA model [46].
Safety concerns in CKD patients with cancer
The ubiquitous expression of erythropoietin receptor
(EPOr) in non-erythroid cells has been associated with
the discovery that EPO has various biological functions in
non-haematopoietic tissues, and a number of experimental
findings link EPO-EPOr signalling to angiogenesis. This
pleiotropic effect is a possible physiological response to is-
chaemia and may elicit the growth of solid tumours. How-
ever, no direct relationship between the presence of EPOr
on tumour cells and tumour proliferation in response to ex-
ogenous EPO has yet been established. The use of ESAs
may also increase the risk of venous thromboembolism in
cancer patients.
ESA therapy is approved in patients with non-
myeloid malignancies who have developed chemotherapy-
associated anaemia in order to decrease transfusion require-
ments. However, safety concerns have been raised in cancer
patients since 2004 [47], particularly in relation to off-label
indications such as anaemia not secondary to chemotherapy
or an Hb target of >12 g/dl.
In May 2007, the Oncologic Drugs Advisory Committee
of the Food and Drug Administration (FDA) reassessed the
ESA-related risks of venous thromboembolism, poorer can-
cer outcomes and cardiovascular disease in cancer patients
receiving chemotherapy [48], and subsequently ordered that
boxed warnings for safety information be added to the labels
of the available ESAs recommending the use of the lowest
ESA dose to increase Hb to a level high enough to avoid
red blood cell transfusions. According to FDA indications,
an Hb target of >12 g/dl should be avoided.
• In the opinion of the ERBP Work Group, ESA therapy
should be cautiously used in patients with CKD and ma-
lignancies as no information is available concerning the
risk of mortality and tumour growth in this subset of
patients.
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Appendix: summary of recommendations
EBPG 2004 KDOQI 2006/2007 ERBP: anaemia group position, 2008
Definition of anaemia Hb <11. 5 in women Hb <12 in females Hb <12 in females
Hb <13.5 in men ≤70 years Hb <13.5 in males Hb <13.5 in males
Hb <12 in men >70 years
Haemoglobin target Hb >11 g/dl; Hb >14 g/dl not
desirable (>12 g/dl in CVD)
aGenerally Hb 11–12 g/dl, target
Hb should not be >13 g/dl
Generally Hb 11–12 g/dl target Hb should not be
>13 g/dl
Targets for iron therapy TSAT (%) TSAT (%) TSAT (%)
Lower limit: 20 Lower limit: ≥20 Lower limit: ≥20
Target: 30–50 Ferritin Ferritin
Ferritin (ng/ml) Lower limit: 100 in non-HD,
200 in HD
Lower limit: 100 in non-HD, 200 in HD
Lower limit: 100 Do not routinely exceed 500 Do not routinely exceed 500
Target 200–500
Pure red cell aplasia
sc Eprex R© Contraindicated Not sold in the USA Readmitted for s.c. use, i.v. use already possible
Retreatment of PRCA
pts with ESA
Insufficient information to give
recommendations
− Careful rechallenge possible, especially in the
absence of anti-EPO antibodies
New erythropoiesis
stimulating agents
Epoetin delta − − Use as other rHuEPOs
CERA Starting dose: 0.6 µg/kg
Frequency: once every 2 weeks for correction; once
every 4 weeks for maintenance
Administration route: i.v. or s.c.
Biosimilars Use as originator compounds, strict post marketing
surveillance, only IV administration
HX575 and Epoetin
zeta
− − Use as epoetin alpha; strict post-marketing
surveillance
CKD patients with cancer − − Use caution; do not aim for Hb >12 g/dl
aRecommendation from the 2007 KDOQI revision about Hb target [3].
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Introduction
Despite major recent therapeutic improvements, septic
shock remains a leading cause of mortality in intensive
care patients [1]. For more than a decade, it has been
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advocated [2,3] that the reduction of blood cytokine lev-
els could, at least theoretically, lead to reduced mortality.
However, in view of the complexity of the pharmacody-
namics and pharmacokinetics of cytokines, this concept
seems too oversimplified to apply. In this issue of the jour-
nal, Rimmele´ and co-authors attempt to demonstrate that
high-volume haemofiltration (HVHF) with enhanced ad-
sorption (EA) can modulate and ameliorate sepsis-induced
haemodynamical instability [4]. It is suggested in this paper
that membranes with EA are key and that increased extrac-
tion from the central circulation is sufficient to obtain a
beneficial clinical effect. It seems at least theoretically rea-
sonable that effective removal of mediators from the tissue,
where they are harmful, and transporting them to the cen-
tral circulation must be effective. Therefore, HVHF and EA
must work synergistically in this model. In order to consol-
idate this hypothesis, it seems fruitful to discuss the three
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